These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1140 related articles for article (PubMed ID: 38720342)

  • 1. Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives.
    Lin H; Liu C; Hu A; Zhang D; Yang H; Mao Y
    J Hematol Oncol; 2024 May; 17(1):31. PubMed ID: 38720342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immature myeloid cells in the tumor microenvironment: Implications for immunotherapy.
    Kamran N; Chandran M; Lowenstein PR; Castro MG
    Clin Immunol; 2018 Apr; 189():34-42. PubMed ID: 27777083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunosuppressive Myeloid Cells' Blockade in the Glioma Microenvironment Enhances the Efficacy of Immune-Stimulatory Gene Therapy.
    Kamran N; Kadiyala P; Saxena M; Candolfi M; Li Y; Moreno-Ayala MA; Raja N; Shah D; Lowenstein PR; Castro MG
    Mol Ther; 2017 Jan; 25(1):232-248. PubMed ID: 28129117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glioblastoma Myeloid-Derived Suppressor Cell Subsets Express Differential Macrophage Migration Inhibitory Factor Receptor Profiles That Can Be Targeted to Reduce Immune Suppression.
    Alban TJ; Bayik D; Otvos B; Rabljenovic A; Leng L; Jia-Shiun L; Roversi G; Lauko A; Momin AA; Mohammadi AM; Peereboom DM; Ahluwalia MS; Matsuda K; Yun K; Bucala R; Vogelbaum MA; Lathia JD
    Front Immunol; 2020; 11():1191. PubMed ID: 32625208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Emerging Role of Myeloid-Derived Suppressor Cells in the Glioma Immune Suppressive Microenvironment.
    Mi Y; Guo N; Luan J; Cheng J; Hu Z; Jiang P; Jin W; Gao X
    Front Immunol; 2020; 11():737. PubMed ID: 32391020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Explicating the Pivotal Pathogenic, Diagnostic, and Therapeutic Biomarker Potentials of Myeloid-Derived Suppressor Cells in Glioblastoma.
    Richard SA
    Dis Markers; 2020; 2020():8844313. PubMed ID: 33204365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis.
    Alban TJ; Alvarado AG; Sorensen MD; Bayik D; Volovetz J; Serbinowski E; Mulkearns-Hubert EE; Sinyuk M; Hale JS; Onzi GR; McGraw M; Huang P; Grabowski MM; Wathen CA; Ahluwalia MS; Radivoyevitch T; Kornblum HI; Kristensen BW; Vogelbaum MA; Lathia JD
    JCI Insight; 2018 Nov; 3(21):. PubMed ID: 30385717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New Insights into the Multifaceted Role of Myeloid-Derived Suppressor Cells (MDSCs) in High-Grade Gliomas: From Metabolic Reprograming, Immunosuppression, and Therapeutic Resistance to Current Strategies for Targeting MDSCs.
    Lakshmanachetty S; Cruz-Cruz J; Hoffmeyer E; Cole AP; Mitra SS
    Cells; 2021 Apr; 10(4):. PubMed ID: 33919732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of myeloid cells in the immunosuppressive microenvironment in gliomas.
    Locarno CV; Simonelli M; Carenza C; Capucetti A; Stanzani E; Lorenzi E; Persico P; Della Bella S; Passoni L; Mavilio D; Bonecchi R; Locati M; Savino B
    Immunobiology; 2020 Jan; 225(1):151853. PubMed ID: 31703822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myeloid-Derived Suppressive Cells Promote B cell-Mediated Immunosuppression via Transfer of PD-L1 in Glioblastoma.
    Lee-Chang C; Rashidi A; Miska J; Zhang P; Pituch KC; Hou D; Xiao T; Fischietti M; Kang SJ; Appin CL; Horbinski C; Platanias LC; Lopez-Rosas A; Han Y; Balyasnikova IV; Lesniak MS
    Cancer Immunol Res; 2019 Dec; 7(12):1928-1943. PubMed ID: 31530559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional assay to assess T-cell inhibitory properties of myeloid derived suppressor cells (MDSCs) isolated from the tumor microenvironment of murine glioma models.
    Alghamri MS; Kamran N; Kadiyala P; Lowenstein PR; Castro MG
    Methods Enzymol; 2020; 632():215-228. PubMed ID: 32000897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered Metabolism in Glioblastoma: Myeloid-Derived Suppressor Cell (MDSC) Fitness and Tumor-Infiltrating Lymphocyte (TIL) Dysfunction.
    Di Ianni N; Musio S; Pellegatta S
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33923299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypoxia within the glioblastoma tumor microenvironment: a master saboteur of novel treatments.
    Feldman L
    Front Immunol; 2024; 15():1384249. PubMed ID: 38994360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer Stem Cell-Secreted Macrophage Migration Inhibitory Factor Stimulates Myeloid Derived Suppressor Cell Function and Facilitates Glioblastoma Immune Evasion.
    Otvos B; Silver DJ; Mulkearns-Hubert EE; Alvarado AG; Turaga SM; Sorensen MD; Rayman P; Flavahan WA; Hale JS; Stoltz K; Sinyuk M; Wu Q; Jarrar A; Kim SH; Fox PL; Nakano I; Rich JN; Ransohoff RM; Finke J; Kristensen BW; Vogelbaum MA; Lathia JD
    Stem Cells; 2016 Aug; 34(8):2026-39. PubMed ID: 27145382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different T-cell subsets in glioblastoma multiforme and targeted immunotherapy.
    Wang H; Zhou H; Xu J; Lu Y; Ji X; Yao Y; Chao H; Zhang J; Zhang X; Yao S; Wu Y; Wan J
    Cancer Lett; 2021 Jan; 496():134-143. PubMed ID: 33022290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suberanilohydroxamic acid (SAHA), a HDAC inhibitor, suppresses the effect of Treg cells by targeting the c-Myc/CCL1 pathway in glioma stem cells and improves PD-L1 blockade therapy.
    Sun T; Liu B; Cai L; Zhou Y; Yang W; Li Y
    J Neurooncol; 2024 Jul; 168(3):457-471. PubMed ID: 38652401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment.
    Pearson JRD; Cuzzubbo S; McArthur S; Durrant LG; Adhikaree J; Tinsley CJ; Pockley AG; McArdle SEB
    Front Immunol; 2020; 11():582106. PubMed ID: 33178210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glioma-derived CCL2 and CCL7 mediate migration of immune suppressive CCR2
    Takacs GP; Kreiger CJ; Luo D; Tian G; Garcia JS; Deleyrolle LP; Mitchell DA; Harrison JK
    Front Immunol; 2022; 13():993444. PubMed ID: 36685592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism and therapeutic potential of tumor-immune symbiosis in glioblastoma.
    Pang L; Khan F; Heimberger AB; Chen P
    Trends Cancer; 2022 Oct; 8(10):839-854. PubMed ID: 35624002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myeloid-derived suppressor cells (MDSCs) in brain cancer: challenges and therapeutic strategies.
    Salemizadeh Parizi M; Salemizadeh Parizi F; Abdolhosseini S; Vanaei S; Manzouri A; Ebrahimzadeh F
    Inflammopharmacology; 2021 Dec; 29(6):1613-1624. PubMed ID: 34613567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.